Pharma News
Takeda's TAK-861 Shows Promising Results in Phase IIb Trial for Narcolepsy Type 1
![](https://meefro.com/wp-content/uploads/2024/02/Takeda039s-TAK-861-Shows-Promising-Results-in-Phase-IIb-Trial-for-780x470.png)
Novel oral orexin receptor 2 agonist produced statistically significant and clinically meaningful improvements in wakefulness compared with placebo in patients with narcolepsy type 1.
Source link
#Takeda039s #TAK861 #Shows #Promising #Results #Phase #IIb #Trial #Narcolepsy #Type